Loading…
Loading…
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the tr
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti.
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase.
Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setbacks.
Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript